PeptideCompare5-Amino-1MQ — EU research guide.
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a cell-permeable small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in adipose tissue. It is studied for fat loss and NAD+ pathway regulation.
What is 5-Amino-1MQ?
5-Amino-1MQ selectively inhibits NNMT, which consumes SAM (S-adenosylmethionine) to methylate nicotinamide, reducing NAD+ availability and cellular energy expenditure. By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ levels and increases metabolic rate in adipocytes. It is not a peptide but a quinolinium derivative that frequently appears in research compound catalogues alongside peptides.
What does the research show?
Mouse studies show reduced adipogenesis, lower fat mass and improved insulin sensitivity without caloric restriction. In diet-induced obese mice, 5-Amino-1MQ treatment reduced fat mass ~7% versus controls. The NNMT/NAD+ axis represents a mechanistically distinct fat-loss target from GLP-1 or GH pathways. No human trials as of mid-2026.
EU legal status
Not approved anywhere. Research compound only. Available from EU vendors for laboratory metabolic research.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
5-Amino-1MQ across EU suppliers
COA-verified EU vendors · Updated monthly